PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis

被引:153
作者
Carter, Laura L.
Leach, Michael W.
Azoitei, Mihai L.
Cui, Junqing
Pelker, Jeffrey W.
Jussif, Jason
Benoit, Steve
Ireland, Gretchen
Luxenberg, Deborah
Askew, G. Roger
Milarski, Kim L.
Groves, Christopher
Brown, Tom
Carito, Brenda A.
Percival, Karen
Carreno, Beatriz M.
Collins, Mary
Marusic, Suzana
机构
[1] Wyeth Res, Inflammat, Cambridge, MA 02140 USA
[2] Exploratory Drug Safety, Andover, MA 01810 USA
[3] Biol Technol, Andover, MA 01810 USA
[4] Wyeth Res, Biol Technol, Cambridge, MA 02140 USA
关键词
EAE; multiple sclerosis; costimulation; PD-1; PD-L1; PD-L2;
D O I
10.1016/j.jneuroim.2006.10.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interactions between PD-1 and its two differentially expressed ligands, PD-L1 and PD-L2, attenuate T cell activation and effector function. To determine the role of these molecules in autoimmunc disease of the CNS, PD-1-/-, PD-L1-/- and PD-L2-/- mice were generated and immunized to induce experimental autommume encephalomyelitis (EAE). PD-1-/- and PD-Ll-/- mice developed more severe EAE than wild type and PD-L2-/- mice. Consistent with this, PD-1-/- and PD-Ll-/- cells produced elevated levels of the proinflammatory cytokines IFN-gamma, TNF, IL-6 and IL-17. These results demonstrate that interactions between PD-1/PD-L1, but not PD-1/PDL-2, are crucial in attenuating T cell responses in EAE. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:124 / 134
页数:11
相关论文
共 56 条
[1]   Immunotherapeutic approaches in multiple sclerosis [J].
Adorini, L .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 223 (01) :13-24
[2]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[3]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[4]   The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system [J].
Becher, B ;
Durell, BG ;
Miga, AV ;
Hickey, WF ;
Noelle, RJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (08) :967-974
[5]   Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses [J].
Bennett, F ;
Luxenberg, D ;
Ling, V ;
Wang, IM ;
Marquette, K ;
Lowe, D ;
Khan, N ;
Veldman, G ;
Jacobs, KA ;
Valge-Archer, VE ;
Collins, M ;
Carreno, BM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (02) :711-718
[6]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[7]   Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism [J].
Blazar, BR ;
Carreno, BM ;
Panoskaltsis-Mortari, A ;
Carter, L ;
Iwai, Y ;
Yagita, H ;
Nishimura, H ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1272-1277
[8]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[9]   Therapeutic opportunities in the B7/CD28 family of ligands and receptors [J].
Carreno, BM ;
Carter, LL ;
Collins, M .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) :424-430
[10]   The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses [J].
Carreno, BM ;
Collins, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :29-53